Name (Synonyms) | Correlation | |
---|---|---|
drug2025 | PET/CT Scan Wiki | 0.71 |
drug2071 | Patient-centred advice on Telephone Consultation in TB Patients: Wiki | 0.71 |
drug2668 | Sputum collection Wiki | 0.71 |
drug428 | Blood Collection Wiki | 0.71 |
drug3021 | Urine collection Wiki | 0.71 |
drug1481 | Isoniazid, Rifampicin, Pyrazinamide and Ethambutol Wiki | 0.71 |
drug2551 | Saliva collection Wiki | 0.32 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
Background: Tuberculosis (TB) is a bacterial lung infection. Typical treatment using anti-TB drugs lasts about 6 months. Some people with less severe TB might not need to take the drugs that long. Researchers think a PET/CT lung scan along with estimating how much TB is in the lungs might show who will be cured after only 4 months of treatment. Objective: To demonstrate that 4 months of treatment is not inferior to 6 months of treatment for people with less severe TB. Eligibility: People 18-75 years old who have TB treatable with standard TB drugs Design: Participants will be screened with: Medical history Physical exam Blood and urine tests HIV test Sputum sample: Participants will be asked to cough sputum into a cup. Chest x-ray Participants will start TB drugs. They will have visits at weeks 1, 2, 4, 8, 12, and about 6 more times during the 18-month study. Visits include: Sputum samples Physical exam Blood tests PET/CT scans at 2-3 visits: Participants fast for about 6 hours before the scan. Participants get FDG, a type of sugar that gives off a small amount of radiation, through an arm vein. They lie on a table in a machine that takes pictures of the body. Chest x-rays at 1-2 visits Participants who we believe are likely to be cured at 4 months will be randomly assigned to get either 6 months of treatment or 4 months of treatment. Participants may be asked to join a substudy using their sputum samples or additional blood tests.
Description: Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm.
Measure: Comparison of the rate of treatment success at 18 months (after treatment initiation) between Arms B and C. Time: 18 monthsDescription: The difference (and 95% confidence interval) in treatment success rates between a combined A+B Arm (with Arm A participants selected to represent a true 6-month standard of care population) and a combined Arm A+C (with the remaining Arm A participants selected to represent a treatment shortening strategy arm, and no overlap in Arm A participants assigned to B and C).
Measure: Radiologic, Immunologic and microbiologic measures Time: 18 monthsThe COVID-19 pandemic might be an opportunity to review and refine our practices in anti TB treatment. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective. The aim of the study is to assess the efficiency and the satisfaction with telephone consultation for the pharmacist and the TB patient. The study was conducted in tertiary care hospital TB control centres patients.
Description: To improve patient centered care/patient prescription refil
Measure: Efficiency of the telephone consultation, Time: 2 MonthsDescription: Patient satisfaction Patient satisfaction resulting from pharmacist-led pharmaceutical care will be assessed Patient satisfaction feedback (PSF)
Measure: Patient satisfaction Time: 2 Month